What is Seven Bridges?
Founded in 2009, Seven Bridges operates at the intersection of high-performance computing and molecular biology. The company provides a sophisticated, cloud-native platform designed to facilitate the collaborative analysis of millions of genomes. By integrating diverse biomedical datasets, the platform serves as a foundational tool for researchers in pharmaceutical, biotech, and academic environments. Its market position is further bolstered by its role as a Trusted Partner to the National Institutes of Health, granting it unique access to some of the world's most comprehensive cancer genomics repositories. This technical moat, combined with its global footprint across Cambridge, London, and San Francisco, positions Seven Bridges as an essential utility for the future of personalized healthcare.
How much funding has Seven Bridges raised?
Seven Bridges has raised a total of $63.3M across 4 funding rounds:
Grant
$2.9M
Series A
$45M
Debt
$350K
Series C
$15M
Grant (2015): $2.9M with participation from Genomics England
Series A (2016): $45M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series C (2021): $15M, investors not publicly disclosed
Key Investors in Seven Bridges
Genomics England
A government-owned company established to deliver the 100,000 Genomes Project, focusing on the integration of genomic medicine into the healthcare system.
Undisclosed Investor
An institutional participant providing capital to support the scaling of enterprise-grade biomedical data infrastructure.
Undisclosed Investor
A strategic backer focused on the intersection of cloud computing and life sciences research.
What's next for Seven Bridges?
With the recent influx of capital, Seven Bridges is well-positioned to deepen its enterprise-level offerings and expand its footprint in the drug discovery pipeline. The strategic focus will likely shift toward enhancing the interoperability of its platform with emerging AI-driven diagnostic tools, thereby increasing the velocity of clinical research. As the demand for precision medicine continues to accelerate, the company is expected to leverage its existing partnerships with large-scale genomics projects to capture a larger share of the pharmaceutical R&D market. Future growth will be predicated on maintaining its regulatory compliance and data security standards, which remain the primary drivers for its adoption among high-stakes government and clinical research institutions.
See full Seven Bridges company page
